Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide)

A. Zalatnai, Zsolt Szegedi, Jozsef Bocsi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The antiproliferative effect of octreotide (Sandostatin) is partly attributed to induction of apoptosis in the given tumors. In this work, apoptosis was assessed in human pancreatic carcinoma xenografts after a 4-week high-dose Sandostatin treatment. Materials and Methods: Subcutaneously growing human pancreatic cancer xenografts (PZX-5) in immunosuppressed mice were treated with 500 μg/kgb.w. Sandostatin twice a day ip. for 4 weeks. Apoptosis was evaluated by means of conventional histology, Apoptag-immunohistochemistry and flow cytometry. Results: The Sandostatin-treatment resulted in a decreased tumor volume in 9 out of 16 animals. Immunohistochemical detection of apoptosis by Apoptag revealed a 75-fold increase of the positively stained tumorous nuclei (210.9 ± 53.9 per square mm) versus nontreated tumors (2.8 ± 0.5 per square mm). The sub-G1 fraction was 3.61 ± 0.4% in untreated samples while it doubled after treatment (p <0.001) Conclusion: A 4-week octreotide (Sandostatin) treatment induced significantly increased apoptosis in human pancreatic carcinoma xenografts evidenced by morphological studies and Apoptag-immunohistochemistry, and these results were clearly reinforced by flow cytometry.

Original languageEnglish
Pages (from-to)1663-1666
Number of pages4
JournalAnticancer Research
Volume20
Issue number3 A
Publication statusPublished - 2000

Fingerprint

Octreotide
Pancreatic Neoplasms
Heterografts
Apoptosis
Flow Cytometry
Immunohistochemistry
Therapeutics
Tumor Burden
Neoplasms
Histology

Keywords

  • Apoptosis
  • Human tumors
  • Octreotide
  • Pancreatic cancer
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide). / Zalatnai, A.; Szegedi, Zsolt; Bocsi, Jozsef.

In: Anticancer Research, Vol. 20, No. 3 A, 2000, p. 1663-1666.

Research output: Contribution to journalArticle

@article{e1d36341916345d4aa3feefda86e6d7e,
title = "Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide)",
abstract = "Background: The antiproliferative effect of octreotide (Sandostatin) is partly attributed to induction of apoptosis in the given tumors. In this work, apoptosis was assessed in human pancreatic carcinoma xenografts after a 4-week high-dose Sandostatin treatment. Materials and Methods: Subcutaneously growing human pancreatic cancer xenografts (PZX-5) in immunosuppressed mice were treated with 500 μg/kgb.w. Sandostatin twice a day ip. for 4 weeks. Apoptosis was evaluated by means of conventional histology, Apoptag-immunohistochemistry and flow cytometry. Results: The Sandostatin-treatment resulted in a decreased tumor volume in 9 out of 16 animals. Immunohistochemical detection of apoptosis by Apoptag revealed a 75-fold increase of the positively stained tumorous nuclei (210.9 ± 53.9 per square mm) versus nontreated tumors (2.8 ± 0.5 per square mm). The sub-G1 fraction was 3.61 ± 0.4{\%} in untreated samples while it doubled after treatment (p <0.001) Conclusion: A 4-week octreotide (Sandostatin) treatment induced significantly increased apoptosis in human pancreatic carcinoma xenografts evidenced by morphological studies and Apoptag-immunohistochemistry, and these results were clearly reinforced by flow cytometry.",
keywords = "Apoptosis, Human tumors, Octreotide, Pancreatic cancer, Xenograft",
author = "A. Zalatnai and Zsolt Szegedi and Jozsef Bocsi",
year = "2000",
language = "English",
volume = "20",
pages = "1663--1666",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide)

AU - Zalatnai, A.

AU - Szegedi, Zsolt

AU - Bocsi, Jozsef

PY - 2000

Y1 - 2000

N2 - Background: The antiproliferative effect of octreotide (Sandostatin) is partly attributed to induction of apoptosis in the given tumors. In this work, apoptosis was assessed in human pancreatic carcinoma xenografts after a 4-week high-dose Sandostatin treatment. Materials and Methods: Subcutaneously growing human pancreatic cancer xenografts (PZX-5) in immunosuppressed mice were treated with 500 μg/kgb.w. Sandostatin twice a day ip. for 4 weeks. Apoptosis was evaluated by means of conventional histology, Apoptag-immunohistochemistry and flow cytometry. Results: The Sandostatin-treatment resulted in a decreased tumor volume in 9 out of 16 animals. Immunohistochemical detection of apoptosis by Apoptag revealed a 75-fold increase of the positively stained tumorous nuclei (210.9 ± 53.9 per square mm) versus nontreated tumors (2.8 ± 0.5 per square mm). The sub-G1 fraction was 3.61 ± 0.4% in untreated samples while it doubled after treatment (p <0.001) Conclusion: A 4-week octreotide (Sandostatin) treatment induced significantly increased apoptosis in human pancreatic carcinoma xenografts evidenced by morphological studies and Apoptag-immunohistochemistry, and these results were clearly reinforced by flow cytometry.

AB - Background: The antiproliferative effect of octreotide (Sandostatin) is partly attributed to induction of apoptosis in the given tumors. In this work, apoptosis was assessed in human pancreatic carcinoma xenografts after a 4-week high-dose Sandostatin treatment. Materials and Methods: Subcutaneously growing human pancreatic cancer xenografts (PZX-5) in immunosuppressed mice were treated with 500 μg/kgb.w. Sandostatin twice a day ip. for 4 weeks. Apoptosis was evaluated by means of conventional histology, Apoptag-immunohistochemistry and flow cytometry. Results: The Sandostatin-treatment resulted in a decreased tumor volume in 9 out of 16 animals. Immunohistochemical detection of apoptosis by Apoptag revealed a 75-fold increase of the positively stained tumorous nuclei (210.9 ± 53.9 per square mm) versus nontreated tumors (2.8 ± 0.5 per square mm). The sub-G1 fraction was 3.61 ± 0.4% in untreated samples while it doubled after treatment (p <0.001) Conclusion: A 4-week octreotide (Sandostatin) treatment induced significantly increased apoptosis in human pancreatic carcinoma xenografts evidenced by morphological studies and Apoptag-immunohistochemistry, and these results were clearly reinforced by flow cytometry.

KW - Apoptosis

KW - Human tumors

KW - Octreotide

KW - Pancreatic cancer

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=0033866848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033866848&partnerID=8YFLogxK

M3 - Article

C2 - 10928088

AN - SCOPUS:0033866848

VL - 20

SP - 1663

EP - 1666

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -